Nature Reviews Cardiology, Published online: 19 June 2026; doi:10.1038/s41569-026-01313-8In this Review, Santovito and colleagues provide an overview of epigenetic regulation in atherosclerosis, focusing on how epigenetic modifications guide cell-specific transcriptional programmes in vascular endothelial cells, vascular smooth muscle cells, and immune cells to regulate cell plasticity and intercellular communication. They also discuss translational opportunities and the challenges of using epigenetic drugs to treat atherosclerotic cardiovascular disease.

Nature Reviews Cardiology, Published online: 18 June 2026; doi:10.1038/s41569-026-01310-xClimate change is systematically degrading the quality, diversity and nutritional composition of global food systems, yet the cardiometabolic consequences of these disruptions are rarely discussed. We examine the dietary pathways through which climate change could drive cardiometabolic disease and explain why the field of preventive cardiology can no longer afford to ignore them.

Nature Reviews Cardiology, Published online: 16 June 2026; doi:10.1038/s41569-026-01304-9In this Review, Nerlekar and colleagues describe how the collective biology of adipose depots, rather than quantity alone, drives cardiometabolic risk, highlight how patterns of fat distribution specific to sex and ethnicity can modulate this risk, and summarize numerous pharmacological interventions to target adipose tissue for the reduction of cardiometabolic risk.

Nature Reviews Cardiology, Published online: 09 June 2026; doi:10.1038/s41569-026-01315-6In patients with advanced, symptomatic heart failure with reduced ejection fraction refractory to guideline-directed therapy, transplantation of a tissue allograft produced from induced pluripotent stem cells promotes heart remuscularization and leads to increases in heart wall thickness, left ventricular ejection fraction and quality of life at 3 months, according to an interim analysis of the ongoing, phase I–II BioVAT-HF clinical trial.

Nature Reviews Clinical Oncology, Published online: 19 June 2026; doi:10.1038/s41571-026-01165-8Over the past decades, cancer epidemiology trends have substantially shifted in China, with a rapid increase in incidence of cancers that are most common in high-income countries and a substantial decline in incidence of cancers historically prevalent in China. The authors of this Review provide an overview of cancer epidemiology in China, a major contributor to global cancer burden, and discuss national cancer control policies and targets.

Nature Reviews Clinical Oncology, Published online: 17 June 2026; doi:10.1038/s41571-026-01164-9Three antibody–drug conjugates (ADCs) are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 and tisotumab vedotin for cervical cancer (independent of tissue factor expression). The authors of this Review discuss current priorities in the clinical development of ADCs for gynaecological cancers, such as identifying novel targets, understanding mechanisms of resistance and sequencing strategies, and managing toxicities, highlighting key advances and future opportunities.

Nature Reviews Clinical Oncology, Published online: 12 June 2026; doi:10.1038/s41571-026-01177-4Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia

Nature Reviews Clinical Oncology, Published online: 11 June 2026; doi:10.1038/s41571-026-01172-9Adjuvant selpercatinib shows benefit in patients with NSCLC